Skip to content

Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants

Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01376869
Enrollment
150
Registered
2011-06-20
Start date
2011-06-30
Completion date
2011-12-31
Last updated
2012-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Modulation of Cognition, Mood Modulation

Keywords

Hops, Mood, Cognitive Function, Bioavailability, Satiety, Blood Pressure, Heart rate

Brief summary

Hops have been used for many years for their supposed sedative and anxiety reducing properties and can be found in many natural remedies for stress, anxiety and sleeping that are already available to buy. However, human trials investigating the effects of hops have so far been limited to the effects of the combination of hops and valerian in relation to sleep. Such studies have identified that a valerian-hops mixture can result in improved sleep but Valerian alone has no effect. The current study aims to investigate the effect of hops alone in healthy human participants aged 18-35 years.

Interventions

DIETARY_SUPPLEMENTHops Extract

All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.

All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.

Sponsors

The New Zealand Institute of Plant and Food Research Ltd.
CollaboratorOTHER_GOV
Northumbria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Male/female, * Healthy * Age 18-35 years old * Non smoker * Proficient in English * Not taking any herbal or prescription medications * Not pregnant seeking to become pregnant or breastfeeding

Exclusion criteria

* Allergy or hypersensitivity to any of the ingredients contained in the investigational product or any other foodstuff. * Vegetarian (as the capsules contain gelatine). * Have a history of neurological, vascular or psychiatric illness (including depressive illness and anxiety). * Have a current/ history of drug or alcohol abuse. * Currently take medication (excluding the contraceptive pill). * High Blood Pressure (\>140/90) * BMI outside of the range 18- 34.9

Design outcomes

Primary

MeasureTime frameDescription
Moodacross 3 hours* Mood as assessed by STAI, Bond-Lader mood scales, POMS, DEQ and stress/euphoria/sedation visual analogue scales (VAS). * The shift in mood (STAI, Bond-Lader, POMS, DEQ, Stress/Euphoria/Sedation VAS) inculcated by completion of cognitive tasks. * Heart rate and blood pressure. * The modulation of blood pressure and heart rate inculcated by completion of cognitive tasks.

Secondary

MeasureTime frameDescription
Satietyacross 3 hours* Satiety as assessed by VAS (hungry/full/desire to eat/food intake). * The modulation of satiety (VAS) inculcated by completion of the cognitive tasks.
Bioavailability of Hopsacross 3 hours• Plasma hops levels are to be examined to assess bioavailability.
Cognitionacross 3 hours* Performance on working memory tasks (2-back and logical reasoning). * Performance on serial subtraction element of a dual task. * Performance on word and picture recognition tasks.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026